November 10, 2016 - Supplement: Biosimilars in Oncology   (View All Issues)

Robert Rifkin, MD, FACP, Guest Editor  / November 10, 2016 - Supplement: Biosimilars in Oncology

Introduction

As expensive cancer biologics move off patent, biosimilar products are coming on board. These are highly similar versions of licensed biologics that demonstrate near-fingerprint identity to their reference products in terms of structure and potency. Biosimilars represent a major opportunity for...

Guest Editor, Robert Rifkin, MD, FACP, Corey Cutler, MD, MPH, Pere Gascón, MD, and Mark McCamish, MD, PhD  / November 10, 2016 - Supplement: Biosimilars in Oncology

Biosimilars in Oncology

In a Roundtable Discussion held during the 2015 American Society of Hematology (ASH) Annual Meeting, several experts addressed questions related to biosimilar products and gauged the potential impact of these drugs on oncology care. These experts included Robert Rifkin, MD, FACP, Medical Director...